CN113677375B - 氟化硅受体取代的放射性药物及其前体 - Google Patents

氟化硅受体取代的放射性药物及其前体 Download PDF

Info

Publication number
CN113677375B
CN113677375B CN202080017181.2A CN202080017181A CN113677375B CN 113677375 B CN113677375 B CN 113677375B CN 202080017181 A CN202080017181 A CN 202080017181A CN 113677375 B CN113677375 B CN 113677375B
Authority
CN
China
Prior art keywords
amino acid
group
hydrophilic
bond
sifa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080017181.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113677375A (zh
Inventor
D·迪卡洛
H-J·韦斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of CN113677375A publication Critical patent/CN113677375A/zh
Application granted granted Critical
Publication of CN113677375B publication Critical patent/CN113677375B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202080017181.2A 2019-01-30 2020-01-29 氟化硅受体取代的放射性药物及其前体 Active CN113677375B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19154636 2019-01-30
EP19154636.5 2019-01-30
PCT/EP2020/052159 WO2020157128A1 (en) 2019-01-30 2020-01-29 Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof

Publications (2)

Publication Number Publication Date
CN113677375A CN113677375A (zh) 2021-11-19
CN113677375B true CN113677375B (zh) 2024-07-23

Family

ID=65268875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017181.2A Active CN113677375B (zh) 2019-01-30 2020-01-29 氟化硅受体取代的放射性药物及其前体

Country Status (7)

Country Link
US (1) US12576169B2 (https=)
EP (1) EP3917581A1 (https=)
JP (1) JP7421232B2 (https=)
CN (1) CN113677375B (https=)
AU (1) AU2020213892B2 (https=)
BR (1) BR112021012110A2 (https=)
WO (1) WO2020157128A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022018264A1 (en) * 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
JP2024544153A (ja) 2021-11-16 2024-11-28 テクニシェ ユニバーシタット ミュンヘン 溶解した［１８ｆ］フッ化物を含む組成物の調製方法およびその方法によって得ることができる組成物
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10800797B2 (en) 2015-05-26 2020-10-13 California Institute Of Technology Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
HUE070098T2 (hu) 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Prostate-specific membrane antigen as a target for cancer imaging and therapy;A. P. KIESS等;《Q J Nucl Med Mol Imaging》;第59卷;第241-268页 *
Synthesis and in Vitro and in Vivo Evaluation of SiFA-Tagged Bombesin and RGD Peptides as Tumor Imaging Probes for Positron Emission Tomography;Simon Lindner等;《Bioconjugate Chem.》;第25卷;第738-749 页 *

Also Published As

Publication number Publication date
JP2022518598A (ja) 2022-03-15
EP3917581A1 (en) 2021-12-08
WO2020157128A1 (en) 2020-08-06
CA3123738A1 (en) 2020-08-06
AU2020213892B2 (en) 2025-04-10
JP7421232B2 (ja) 2024-01-24
AU2020213892A1 (en) 2021-07-22
BR112021012110A2 (pt) 2021-09-08
US20220096669A1 (en) 2022-03-31
CN113677375A (zh) 2021-11-19
US12576169B2 (en) 2026-03-17

Similar Documents

Publication Publication Date Title
ES2914832T3 (es) Ligandos de PSMA para la formación de imágenes y endorradioterapia
RU2523531C2 (ru) Конъюгаты антагониста пептида аналога бомбезина
CN113677375B (zh) 氟化硅受体取代的放射性药物及其前体
US8414864B2 (en) Gastrin releasing peptide compounds
CN116981486A (zh) 双模式放射性示踪剂和治疗剂
WO2022171869A1 (en) Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
US20240317780A1 (en) Radiopharmaceutical somatostatin receptor ligands and precursors thereof
CA3123738C (en) Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof
US20260027244A1 (en) Silicon-based fluoride acceptor groups for radiopharmaceuticals
WO2024051794A1 (zh) 放射性核素偶联药物及其药物组合物和应用
HK40111230A (zh) 用於靶向细胞表面受体的可裂解放射性配体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant